Clinical application of 1,5-anhydroglucitol measurements in patients with hepatocyte nuclear factor-1α maturity-onset diabetes of the young

2008
journal article
article
26
cris.lastimport.wos2024-04-10T00:54:36Z
dc.abstract.enOBJECTIVE - 1,5-anhydroglucitol (1,5-AG) is a short-term marker of metabolic control in diabetes. Its renal loss is stimulated in hyperglycemic conditions by glycosuria, which results in a lowered plasma concentration. As a low renal threshold for glucose has been described in hepatocyte nuclear factor-1α (HNF-1α) maturity-onset diabetes of the young (MODY), the 1,5-AG level may be altered in these patients. The purpose of this study was to assess the 1,5-AG levels in patients with HNF-1α MODY and in type 2 diabetic subjects with a similar degree of metabolic control. In addition, we aimed to evaluate this particle as a biomarker for HNF-1α MODY. RESEARCH DESIGN AND METHODS - We included 33 diabetic patients from the Polish Nationwide Registry of MODY. In addition, we examined 43 type 2 diabetic patients and 47 nondiabetic control subjects. The 1,5-AG concentration was measured with an enzymatic assay (GlycoMark). Receiver operating characteristic (ROC) curve analysis was used to evaluate 1,5-AG as a screening marker for HNF-1α MODY. RESULTS - The mean 1,5-AG plasma concentration in diabetic HNF-1α mutation carriers was 5.9 μg/ml, and it was lower than that in type 2 diabetic patients (11.0 μg/ml, P = 0.003) and in nondiabetic control subjects (23.9 μg/ml, P < 0.00005). The ROC curve analysis revealed 85.7% sensitivity and 80.0% specificity of 1,5-AG in screening for HNF-1α MODY at the criterion of <6.5 μg/ml in patients with an A1C level between 6.5 and 9.0%. CONCLUSIONS - 1,5-AG may be a useful biomarker for differential diagnosis of patients with HNF-1α MODY with a specific range of A1C, although this requires further investigation. However, the clinical use of this particle in diabetic HNF-1α mutation carriers for metabolic control has substantial limitations.pl
dc.affiliationWydział Lekarski : Klinika Chorób Metabolicznychpl
dc.affiliationWydział Lekarski : Katedra Chorób Metabolicznychpl
dc.affiliationWydział Lekarski : Katedra Chorób Wewnętrznych i Medycyny Wsipl
dc.contributor.authorSkupień, Jan - 152464 pl
dc.contributor.authorGorczyńska-Kosiorz, Sylwiapl
dc.contributor.authorKlupa, Tomasz - 130157 pl
dc.contributor.authorWanic, Krzysztofpl
dc.contributor.authorButton, Eric A.pl
dc.contributor.authorSieradzki, Jacekpl
dc.contributor.authorMałecki, Maciej - 130840 pl
dc.date.accessioned2020-08-27T12:59:12Z
dc.date.available2020-08-27T12:59:12Z
dc.date.issued2008pl
dc.date.openaccess0
dc.description.accesstimew momencie opublikowania
dc.description.number8pl
dc.description.physical1496-1501pl
dc.description.versionostateczna wersja wydawcy
dc.description.volume31pl
dc.identifier.doi10.2337/dc07-2334pl
dc.identifier.eissn1935-5548pl
dc.identifier.issn0149-5992pl
dc.identifier.projectROD UJ / OPpl
dc.identifier.urihttps://ruj.uj.edu.pl/xmlui/handle/item/244744
dc.languageengpl
dc.language.containerengpl
dc.rightsUdzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Bez utworów zależnych 3.0*
dc.rights.licenceCC-BY-NC-ND
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/legalcode*
dc.share.typeinne
dc.subtypeArticlepl
dc.titleClinical application of 1,5-anhydroglucitol measurements in patients with hepatocyte nuclear factor-1α maturity-onset diabetes of the youngpl
dc.title.journalDiabetes Carepl
dc.typeJournalArticlepl
dspace.entity.typePublication
cris.lastimport.wos
2024-04-10T00:54:36Z
dc.abstract.enpl
OBJECTIVE - 1,5-anhydroglucitol (1,5-AG) is a short-term marker of metabolic control in diabetes. Its renal loss is stimulated in hyperglycemic conditions by glycosuria, which results in a lowered plasma concentration. As a low renal threshold for glucose has been described in hepatocyte nuclear factor-1α (HNF-1α) maturity-onset diabetes of the young (MODY), the 1,5-AG level may be altered in these patients. The purpose of this study was to assess the 1,5-AG levels in patients with HNF-1α MODY and in type 2 diabetic subjects with a similar degree of metabolic control. In addition, we aimed to evaluate this particle as a biomarker for HNF-1α MODY. RESEARCH DESIGN AND METHODS - We included 33 diabetic patients from the Polish Nationwide Registry of MODY. In addition, we examined 43 type 2 diabetic patients and 47 nondiabetic control subjects. The 1,5-AG concentration was measured with an enzymatic assay (GlycoMark). Receiver operating characteristic (ROC) curve analysis was used to evaluate 1,5-AG as a screening marker for HNF-1α MODY. RESULTS - The mean 1,5-AG plasma concentration in diabetic HNF-1α mutation carriers was 5.9 μg/ml, and it was lower than that in type 2 diabetic patients (11.0 μg/ml, P = 0.003) and in nondiabetic control subjects (23.9 μg/ml, P < 0.00005). The ROC curve analysis revealed 85.7% sensitivity and 80.0% specificity of 1,5-AG in screening for HNF-1α MODY at the criterion of <6.5 μg/ml in patients with an A1C level between 6.5 and 9.0%. CONCLUSIONS - 1,5-AG may be a useful biomarker for differential diagnosis of patients with HNF-1α MODY with a specific range of A1C, although this requires further investigation. However, the clinical use of this particle in diabetic HNF-1α mutation carriers for metabolic control has substantial limitations.
dc.affiliationpl
Wydział Lekarski : Klinika Chorób Metabolicznych
dc.affiliationpl
Wydział Lekarski : Katedra Chorób Metabolicznych
dc.affiliationpl
Wydział Lekarski : Katedra Chorób Wewnętrznych i Medycyny Wsi
dc.contributor.authorpl
Skupień, Jan - 152464
dc.contributor.authorpl
Gorczyńska-Kosiorz, Sylwia
dc.contributor.authorpl
Klupa, Tomasz - 130157
dc.contributor.authorpl
Wanic, Krzysztof
dc.contributor.authorpl
Button, Eric A.
dc.contributor.authorpl
Sieradzki, Jacek
dc.contributor.authorpl
Małecki, Maciej - 130840
dc.date.accessioned
2020-08-27T12:59:12Z
dc.date.available
2020-08-27T12:59:12Z
dc.date.issuedpl
2008
dc.date.openaccess
0
dc.description.accesstime
w momencie opublikowania
dc.description.numberpl
8
dc.description.physicalpl
1496-1501
dc.description.version
ostateczna wersja wydawcy
dc.description.volumepl
31
dc.identifier.doipl
10.2337/dc07-2334
dc.identifier.eissnpl
1935-5548
dc.identifier.issnpl
0149-5992
dc.identifier.projectpl
ROD UJ / OP
dc.identifier.uri
https://ruj.uj.edu.pl/xmlui/handle/item/244744
dc.languagepl
eng
dc.language.containerpl
eng
dc.rights*
Udzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Bez utworów zależnych 3.0
dc.rights.licence
CC-BY-NC-ND
dc.rights.uri*
http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode
dc.share.type
inne
dc.subtypepl
Article
dc.titlepl
Clinical application of 1,5-anhydroglucitol measurements in patients with hepatocyte nuclear factor-1α maturity-onset diabetes of the young
dc.title.journalpl
Diabetes Care
dc.typepl
JournalArticle
dspace.entity.type
Publication
Affiliations

* The migration of download and view statistics prior to the date of April 8, 2024 is in progress.

Views
11
Views per month
Views per city
Ashburn
4
Wroclaw
2
Draveil
1
Dublin
1
Szczecin
1
Downloads
skupien_klupa_malecki_clinical_et-al_application_of_1_5_anhydroglucitol_measurements_2008.pdf
11
skupien_klupa_malecki_clinical_et-al_application_of_1_5_anhydroglucitol_measurements_2008.odt
4